Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
Roche reports positive late-stage trial results for its lung-cancer drug divarasib, a KRAS G12C inhibitor. The study shows the treatment reduced the risk of death by 44 percent and extended patient survival by nearly six months compared to standard care. These findings position the pill favorably against competing products from Amgen and Bristol Myers Squibb within the oncology market.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Roche announced that its KRAS G12C inhibitor divarasib cut the risk of death by 44% in a late-stage lung cancer trial.
- ✓ The late-stage trial results demonstrated that the Roche lung cancer drug extended survival by nearly six months.
- ✓ Divarasib outperformed competing treatments from rivals Amgen and Bristol Myers Squibb in the study.
What changed
Roche released late-stage trial data showing divarasib extended patient survival and outperformed rival therapies at the ESMO congress.
Live updates
-
Roche Lung-Cancer Drug Divarasib Outperforms Rivals in Trial
Roche reports positive late-stage trial results for its lung-cancer drug divarasib, a KRAS G12C inhibitor. The study shows the treatment reduced the risk of death by 44 percent and extended patient survival by nearly six months compared to standard care. These findings position the pill favorably against competing products from Amgen and Bristol Myers Squibb within the oncology market.
Why it matters
The data were presented at the European Society for Medical Oncology congress, highlighting advancements in targeted cancer therapies. Divarasib targets specific genetic mutations in non-small cell lung cancer, marking a competitive milestone for Roche in the oncology sector. Analysts and industry observers view the late-stage trial success as a significant challenge to established market competitors.
What is confirmed
- Roche announced that its KRAS G12C inhibitor divarasib cut the risk of death by 44% in a late-stage lung cancer trial.
- The late-stage trial results demonstrated that the Roche lung cancer drug extended survival by nearly six months.
- Divarasib outperformed competing treatments from rivals Amgen and Bristol Myers Squibb in the study.
What to watch next
- Regulatory submissions and approvals for divarasib in major markets
- Further commercial uptake and market competition data against Amgen and Bristol Myers Squibb products
confidence 100%Sources used for this update (15)
- straitsresearch.com — Asbestosis Treatment Market Size, Forecast, Demand, 2034
- www.thebionews.net — KDDF CEO Park Yeong-min: “Korean biotech firms set to expand global cooperation, delivering substantial new drug development res....
- www.coherentmarketinsights.com — Rising Demand For Healthcare Professionals And Psychologists
- WSJ — Roche Targets Emerging Oncology Market With New Lung-Cancer Drug
- Reuters — Roche says divarasib cut risk of death 44% in lung cancer trial
- Fierce Biotech — ESMO: Roche touts ‘convincing’ phase 3 KRAS data after win over rivals
- Bloomberg.com — Roche Drug Outshines Amgen, Bristol Rivals in Lung Cancer Study
- Seeking Alpha — Roche lung cancer drug extends survival by nearly six months in late-stage trial (RHHBY:OTCMKTS)
- Endpoints News — Roche takes victory lap with lung cancer pill's win over Amgen, BMS
- STAT — Roche gets a lung cancer win with its KRAS drug divarasib
- FirstWord Pharma — ESMO26: Roche's KRAS G12C inhibitor divarasib lives up to expectations in lung cancer study
- www.biospace.com — GSK restructure will hit home, impacting 'limited' UK roles
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community